Plain-English translation of NCT05186818 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hypertrophic cardiomyopathy research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial studied aficamten, a new medication taken by mouth once daily, in adults with obstructive hypertrophic cardiomyopathy—a condition where the heart muscle becomes abnormally thick and partially blocks blood flow out of the heart. Half of the participants received the medication while the other half received a placebo (an inactive pill that looks identical). Researchers measured whether the medication improved exercise ability and safety over 24 weeks of treatment.
People with this heart condition often struggle with shortness of breath, chest pain, and limited exercise capacity, and current treatments don't work well enough for everyone. This trial was designed to see if this new medication could reduce the heart's obstruction and help patients exercise better and feel less symptomatic.
Participants came to the clinic for visits over 24 weeks and took a daily pill (either the medication or placebo). During the first 6 weeks, the dose was gradually increased based on heart ultrasound results to find the right level for each person. Participants had heart ultrasounds and exercise tests at screening and at the end of treatment to measure how well the medication worked. A participant's regular heart medications remained unchanged during the trial.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
United States